Using the same PD-L1 IHC positivity criteria, a different trial evaluating combination nivolumab plus ipilimumab in advanced melanoma reported a response in 57% of PD-L1 positive and 41% of PD-L1 negative cases [214, 217]. The gene discussed is CD274; the disease is melanoma.